News › Clinical Practice, Industry News, News

Galderma Announces Positive Test Results for Investigational Botulinum Toxin

October 10, 2019

Galderma recently announced the Phase 2 clinical trial results for its novel ready-to-use investigational botulinum toxin, QM1114. The multicenter, randomized, double-blind, placebo-controlled study successfully demonstrated the safety and efficacy of Galderma’s liquid formulation of botulinum toxin type A for the treatment of glabellar lines (frown lines). The Phase 3 clinical trial program will begin soon to support regulatory submissions globally.
Read more at PR Newswire >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • AmSpa CEO Reflects on the Sonya Dakar Case
    • SkinStylus Receives New FDA Clearance for the Improvement of Periorbital Wrinkles for All Skin Types
    • GlossGenius Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • FDA Advisory Committee to Review Seven Peptides for Potential Use in Compounding
    • PDGF, Regenerative Medicine and the Questions Med Spas Can’t Ignore
Advertisement